T cell responses. These results indicate that the incorporation of a modified 5 mC base improves the safety profile of the saRNA vaccine without compromising immunogenicity, supporting further development of this platform as a booster vaccine.
No takes yet. Share an insight, caveat, or question.
Aboshi et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: